There are currently 2335 ongoing clinical trials involving Non-Small Cell Lung Cancer
Of the 2335 trials,895 trials are in Phase II
Furthermore, 533 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Non-Small Cell Lung Cancer, an Oncology condition. The largest number of ongoing clinical trials for Non-Small Cell Lung Cancer is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Non-Small Cell Lung Cancer-related drug trials.
AstraZeneca Plc: The leading ongoing Non-Small Cell Lung Cancer related clinical trial sponsor
AstraZeneca Plc is the top sponsor for Non-Small Cell Lung Cancer-related ongoing clinical trials.
Sun Yat-sen University, National Cancer Institute US, F. Hoffmann-La Roche Ltd and Pfizer Inc are among other notable clinical trial sponsors involved in Non-Small Cell Lung Cancer. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Non-Small Cell Lung Cancer
Pembrolizumab (Keytruda), Nivolumab (Opdivo, Opdyta) and Bevacizumab (Avastin) are among the key marketed drugs involving Non-Small Cell Lung Cancer.
Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist mechanism of action. Pembrolizumab is formulated as lyophilised powder for solution, solution concentrate for intravenous route of administration. Pembrolizumab was first approved in 2014 and is marketed globally in the US, UK, China, Japan, Germany, and France by several prominent pharma giants including Merck Sharp & Dohme Corp.
Nivolumab (Opdivo, Opdyta) is a human IgG4 anti-PD-1 monoclonal antibody. It functions via Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist mechanism of action. Nivolumab is formulated as solution and concentrate solution for intravenous route of administration. Nivolumab was first approved in 2014 and is marketed globally in the US, UK, France, Germany, China and Japan by several prominent pharma giants including Bristol-Myers Squibb Co.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward